Compare AstraZeneca plc (AZN) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Kaltura Inc — how do they compare? AstraZeneca plc trades at $166.71 (market cap $253.13B), while Kaltura Inc trades at $1.27 (market cap $190.22M). The key difference: AstraZeneca plc is far larger — about 1330.7× Kaltura Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals.
| AZN | KLTR | |
|---|---|---|
Market Cap | $253.13B | $190.22M |
Sector | Health | Technology |
52-Week High | $209.48 | $1.97 |
52-Week Low | $137.44 | $1.08 |
Enterprise Value | $279.37B | $172.94M |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
KLTR trades at $1.29, up 0.78% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $180M and narrowing losses, while maintaining a high gross margin of 71.17%. Recent news highlights industry recognition and AI product launches, though cash flow remains negative and equity is thin at $24.39M.
Outlook is mixed: analyst consensus leans buy (44%) with improving profit trends, but high P/B of 41.6 and negative ROE pose valuation risks. Key catalysts include Q2 2026 results on August 5, 2026, while competitive pressure and reliance on AI adoption present ongoing challenges for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
